Poseida Therapeutics, Inc. (PSTX)
Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche)
9.50
0.00 (0.00%)
Inactive · Last trade price
on Jan 7, 2025
Poseida Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Poseida Therapeutics stock have an average target of 9, which predicts a -5.26% decrease from the current stock price of 9.5.
Price Target: $9 (-5.26%)
Analyst Consensus: Hold
No price target forecast data available
* Price targets were last updated on Nov 26, 2024.
Analyst Ratings
The average analyst rating for Poseida Therapeutics stock from 3 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 2 | 2 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 26, 2024 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $20 → $9 | Strong Buy → Hold | Downgrades | $20 → $9 | -5.26% | Nov 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +110.53% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +110.53% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
150.06M
from 64.70M
Increased by 131.92%
Revenue Next Year
44.20M
from 150.06M
Decreased by -70.55%
EPS This Year
-0.97
from -1.37
EPS Next Year
-1.72
from -0.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 163.7M | 73.5M | 46.2M | |||
| Avg | 150.1M | 44.2M | 22.4M | |||
| Low | 138.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 153.0% | -51.0% | 4.5% | |||
| Avg | 131.9% | -70.5% | -49.2% | |||
| Low | 113.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.68 | -1.34 | -0.95 | |||
| Avg | -0.97 | -1.72 | -1.41 | |||
| Low | -1.88 | -2.06 | -1.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.